These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29742643)

  • 21. Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.
    Waterer G; Lord J; Hofmann T; Jouhikainen T
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31964790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections.
    Alosaimy S; Murray KP; Zasowski EJ; Morrisette T; Lagnf AM; Lodise TP; Rybak MJ
    Clin Infect Dis; 2021 Dec; 73(11):e4560-e4567. PubMed ID: 32716506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
    Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM
    J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
    Pai MP; Neely M; Rodvold KA; Lodise TP
    Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
    Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
    Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
    Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
    Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Vancomycin AUC/MIC and Trough Concentration With Early Clinical Response in Enterococcus or Coagulase-Negative Staphylococcus Infection: A Prospective Study.
    Pitayakittiwong C; Sermsappasuk P; Meesing A; Jaisue S
    J Clin Pharmacol; 2024 Aug; 64(8):1006-1014. PubMed ID: 38639115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.
    Fewel N
    J Clin Pharm Ther; 2021 Oct; 46(5):1426-1432. PubMed ID: 34169543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.
    Hahn A; Frenck RW; Allen-Staat M; Zou Y; Vinks AA
    Ther Drug Monit; 2015 Oct; 37(5):619-25. PubMed ID: 26378371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
    Moise-Broder PA; Forrest A; Birmingham MC; Schentag JJ
    Clin Pharmacokinet; 2004; 43(13):925-42. PubMed ID: 15509186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.
    Kishk OA; Lardieri AB; Heil EL; Morgan JA
    J Pediatr Pharmacol Ther; 2017; 22(1):41-47. PubMed ID: 28337080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.
    Tsutsuura M; Moriyama H; Kojima N; Mizukami Y; Tashiro S; Osa S; Enoki Y; Taguchi K; Oda K; Fujii S; Takahashi Y; Hamada Y; Kimura T; Takesue Y; Matsumoto K
    BMC Infect Dis; 2021 Feb; 21(1):153. PubMed ID: 33549035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
    Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vancomycin dosing and target attainment in children.
    Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
    J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
    J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.